David Aaron Lehman Sells 5,497 Shares of Pulmonx Co. (NASDAQ:LUNG) Stock

Pulmonx Co. (NASDAQ:LUNG) General Counsel David Aaron Lehman sold 5,497 shares of Pulmonx stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $6.19, for a total transaction of $34,026.43. Following the completion of the sale, the general counsel now owns 197,851 shares of the company’s stock, valued at approximately $1,224,697.69. The trade was a 2.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Pulmonx Price Performance

Shares of NASDAQ LUNG opened at $6.16 on Friday. The firm’s 50-day moving average price is $6.73 and its 200-day moving average price is $6.98. Pulmonx Co. has a 1-year low of $5.46 and a 1-year high of $14.84. The firm has a market capitalization of $243.25 million, a P/E ratio of -4.19 and a beta of 0.69. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40.

Pulmonx (NASDAQ:LUNG) last posted its earnings results on Wednesday, October 30th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. The company had revenue of $20.39 million for the quarter, compared to analyst estimates of $20.39 million. During the same quarter in the prior year, the business posted ($0.39) EPS. Equities research analysts anticipate that Pulmonx Co. will post -1.53 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Stifel Nicolaus decreased their target price on shares of Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Thursday, October 31st. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.67.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. 272 Capital LP purchased a new stake in Pulmonx in the 3rd quarter worth approximately $25,000. nVerses Capital LLC purchased a new stake in shares of Pulmonx during the 3rd quarter valued at $26,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Pulmonx during the 2nd quarter valued at $37,000. Hsbc Holdings PLC purchased a new stake in shares of Pulmonx during the 2nd quarter valued at $93,000. Finally, Mackenzie Financial Corp purchased a new stake in shares of Pulmonx during the 2nd quarter valued at $102,000. 91.04% of the stock is owned by institutional investors.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.